



Resource impact template

Resource impact

Published: 4 February 2026

www.nice.org.uk

NICE has produced a [resource impact template](#) that incorporates the following technology appraisal guidance for treating resectable non-small-cell lung cancer:

- [Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer](#) (2026) NICE technology appraisal guidance 1127
- [Durvalumab with chemotherapy before surgery \(neoadjuvant\) then alone after surgery \(adjuvant\) for treating resectable non-small-cell lung cancer](#) (2025) NICE technology appraisal guidance 1030